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Abstract
This paper considers the manner in which technology is diffused, with a particular emphasis on the
impact on workforce composition as it matures. The lack of quantitative evidence of technology on the
medical labour-force limits our knowledge of the full impact of technological change in the healthcare
sector. We examine the diffusion of PTCA as it replaces CABG in the treatment of cardiovascular dis-
ease in England, estimating the degree to which the workforce reacts to the introduction of the newer
technology, through calculating elasticity of supply measures. Using administrative data we trace the
complementarity between CABG and PTCA during the mature phase of technology adoption, mapped
against an increasing employment of cardiologists over cardiothoracic surgeons. Our findings show ev-
idence of indication creep as PTCA is increasingly expanded to older and sicker patients, and that
cardiothoracic surgery, other than CABG, increases in a manner consistent with replacement activity
and cardiothoracic employment.
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1 Introduction
Technology uptake in health care, although associated with improvements in health outcomes
(Skinner & Staiger 2015) has also been established as a major driver of health care expen-
diture for most developed countries (Newhouse 1992, Okunade & Murthy 2002, Smith et al.
2009, Lamiraud & Lhuillery 2016). The contribution of medical innovation to health care
productivity has been related to the cost-effectiveness of the technology itself (Chandra &
Skinner 2012). Those technologies that have a higher initial unit cost than existing tech-
nologies may be adopted as the higher marginal cost may be offset by high marginal benefits
to patients over the long-run (Skinner & Staiger 2015). Yet even those medical innovations
introduced into the health care sector with a lower initial per unit cost, may increase overall
expenditure through increasing demand.
While this additional impact of demand expansion has been recognised (see, Cutler &
Huckman 2003), there has been little analysis of the manner through which the demand
expansion occurs or the impact that new technology has on labour, and no analysis that we
can point to on the general impact of new technological diffusion as it affects the general
composition of the workforce. This study is, to the best of our knowledge, the first to
provide empirical evidence on the aggregate impacts on labour of the diffusion of a specific
new health care technology as it matures and replaces an older technology. The specific
technology we analyse is Percutaneous Transluminal Coronary Angioplasty (PTCA)1, as it
displaces Coronary Artery Bypass Graft (CABG). PTCA was introduced as a less invasive
and cheaper procedure than the existing technology, CABG to treat cardiovascular disease.
As first noted by Cutler & Huckman (2003), two effects might arise on the introduction
of a new innovation: an expansion and/or substitution effect. An expansion effect occurs
when the technology opens up new treatment possibilities that were previously unavailable.
In addition, there may also be a substitution effect that leads to replacement (partial or
total) of an existing technology. Cutler & Huckman (2003) estimated that the substitution
effect of PTCA over CABG accounted for 25-35% of new PTCAs that followed an initial
expansion effect in the US. McGuire et al. (2010) found similar results for the UK, however,
the substitution effect was lower and the expansion effect was higher in the UK compared to
the estimates suggested by Cutler & Huckman (2003) for the US.
Generally the analysis of health care technology has considered adoption and diffusion
aspects of new technologies in the health care sector largely through issues of quality improve-
ment (McClellan et al. 1994, Cutler & McClellan 2001, Chandra & Skinner 2012). Different
lines of research have focussed on different technology types. Evidence on drug diffusion
(Coscelli & Shum 2004, Crawford & Shum 2005, Serra-Sastre & McGuire 2013), physical
capital (Baker & Phibbs 2000, Baker 2001, Clemens & Gottlieb 2014), health technology
1We use PTCA throughout to include angioplasty as first introduced without stents, as well as the
up-graded technology that includes stents and drug-eluting stents sometimes referred to as PCI
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information (Lammers 2013, Dranove et al. 2015) or surgical procedures (Cutler & Huckman
2003, McGuire et al. 2010) have shed light on different aspects of diffusion such as infor-
mational spillovers, organisational structure and the role of insurance. Some studies have
considered the impact of differential technology adoption on outcomes, mapping adoption
rates and the form of technology adoption to productivity (Skinner & Staiger 2015). While
yet others have considered the rate of substitution between surgical and medical intervention
on resource use and outcomes (Chandra & Staiger 2007).
There has been less analysis of the impact of technology adoption on labour substitutabil-
ity or labour-force composition more generally as the newly adopted technology matures.
While some studies do document specific productivity gains as correlated with differential
technology adoption such as Chandra & Staiger (2007) and Skinner & Staiger (2015), there
has been little examination of workforce composition effects arising as a consequence of tech-
nology adoption and diffusion. Given that the workforce accounts for approximately 60% of
expenditure in most health care systems (Imison & Bohmer 2013), the lack of analysis of the
impact that medical innovations have on staffing is surprising.
The general economics literature has examined the impact of technological change on the
composition of labour inputs, suggesting that new technology adoption is largely skill-biased
(Bekman et al. 1998, Morrison Paul & Siegel 2001, Acemoglu 2002), acting as a substitute
for non-skilled labour and a complement for skilled labour (Autor et al. 2003). Despite the
general conclusion of technological progress inducing a bias towards a complementary, highly
skilled labour force, there are of course sectoral differences in the degree of skill upgrading
across industries (Autor et al. 1998, Ho 2008). In the health care sector, there is sparse
empirical evidence of the potential substitution or complementarity between technology and
labour as new technologies are introduced.
David et al. (2009) examine the impact on hospital specialists of technology uptake in
three diagnostic and treatment technologies and find some evidence of new technology re-
ducing the use of highly specialised labour, with the precise impact differing across different
employment arrangements. They consider the type of capital-embodied technologies used in
Acemoglu & Finkelstein (2008). Acemoglu & Finkelstein (2008) find that moving to a fixed-
price system such as the Medicare Prospective Payment System (PPS) induces an increase in
the capital-labour ratio through a decline in labour and a push for the adoption of new tech-
nologies.2 Of course any predicted impacts of technology on workforce will depend on both
the specific technology under consideration and the institutional context. The TECH Investi-
gators (Bech et al. 2009) show that new technology is associated with a slower rate of up-take
and diffusion in centrally funded jurisdictions than in those that have less central control.
Most empirical evidence focuses on technological change in the form of capital-embodied
2There has been little analysis of capital-labour substitution within the UK NHS, although research
undertaken at the aggregate level finds a strong substitutability between various categories of labour
and capital generally (Gray & McGuire 1989).
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technology, but it is unclear whether technological change that is labour-embedded, as in
the case of some surgical innovations, would lead to a similar labour reallocation. The eco-
nomics literature has focused on the changes in skilled versus non-skilled labour; however,
we examine the impact of technology in labour composition across workforce of the same
skill-type.
The objective of this paper is to examine the introduction of PTCA as a technology,
which has rapidly replaced CABG and assess what happens to both demand for the inter-
vention and the impact on the workforce. All analysis is undertaken within the context of the
English NHS, with data drawn from two large administrative databases. Following Cutler &
Huckman (2003) we initially examine the degree of substitution or complementarity effects
of this less invasive and cheaper technology on CABG. We explicitly concentrate on PTCA
as it approaches maturity in it’s diffusion as a technology, as we wish to consider the per-
manent impacts of technology adoption on demand and the workforce. We then document
the treatment (demand) expansion effect, which we refer to as the indication creep, as the
new technology is rolled out to riskier patient groups. No study considers the actual demand
expansion as we do below, by examining how PTCA is increasingly used for a larger pool
of patients who are older and sicker.3 We then expand the analysis to estimate the degree
to which the workforce reacts to the introduction of the new technology, through calculating
elasticity of supply measures. This is possible as distinct types of medical labour, cardiolo-
gists and cardiothoracic surgeons respectively, perform the two types of intervention. Finally,
we document the displacement of cardiothoracic surgeons workload to other procedures as
PTCA replaces CABG.
Ultimately, we find complementarity among the two technologies in this mature phase
of PTCA adoption, with a 1% increase in CABG volumes associated with a 34% increase
in PTCA volumes across hospitals providing both procedures. We then find that PTCA
is associated with indication creep as output expands through differing patient treatment
populations. In analysing the impact on the workforce, we find that a 1% increase in the
PTCA/CABG relationship increases the workforce ratio (cardiologist over cardiothoracic
surgeons ratio) by 0.6% for the sample of hospitals providing both procedures. A final ef-
fect is that cardiothoracic surgeons are seen to increase the volume of other cardiovascular
procedures, namely valve replacement, that fall within their specialty workload. Overall we
conclude that the diffusion of the new technology has a direct impact through treatment ex-
pansion, and an indirect effect as the composition of the workload for cardiothoracic surgeons
changes.
The paper is structured as follows. We begin by describing our data and presenting some
background on the evolution of PTCA and CABG use within the UK. We follow this by
3Tu et al. (1997) do partially assess the impact of PTCA use as demand expands to more elderly
patients.
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outlining the empirical strategies used to investigate the various impacts of adopting PTCA
over CABG, (the substitution effect, the output expansion associated with the indication
creep of PTCA, the workforce impact and the cardiothoracic surgeon displacement effect),
within the UK NHS. The empirical results of our investigation follow and we finish with
concluding comments.
2 Data and Descriptive Statistics
In order to test empirically the impact of new technology on workforce, we use the Hospital
Episode Statistics (HES), a rich administrative dataset that contains all episodes for patients
admitted into hospitals in England. Our sample includes all HES records from financial year
2000/2001 to financial year 2012/134 for each patient admitted into hospital who had as
main surgery CABG or PTCA based on the procedure codes (OPCS-4). We consider both
elective and emergency admissions5. Each patient record contains clinical information on the
admission date, main operation, date of operation, discharge date and all other operations
the patient might have had as well as the main diagnosis. The dataset also includes organisa-
tional and geographical information, and we are able to link each episode to the anonymised
identifier of the physician performing the intervention.
HES data is aggregated at the provider level to construct a longitudinal dataset that
includes total volumes for PTCA and CABG by provider and year. The final dataset is an
unbalanced panel of 199 providers from 2000 to 2012. PTCA and CABG volumes are adjusted
by population at risk, therefore volumes are over population of individuals aged 45 and
above in the Primary Care Trust (PCT)6 where the provider is located. Figure 1 shows the
population-adjusted volumes for PTCA and CABG7. While the average annual rate of growth
for PTCA was 7.95% during the period 2000-2012, it was -2.43% for CABG, suggesting that
as PTCA matures the demand for CABG is significantly reduced. Providers with volumes of
either PTCA or CABG below 50 procedures per year (less than one intervention per week)
are removed8. After accounting for hospital mergers, the final dataset identifies 79 hospitals
across the period 2000-2012 undertaking sufficient volume of PTCA and/or CABG. Of these
79 providers, 29 hospitals perform both surgeries (PTCA and CABG), while the remainder
4Hereafter, we refer to each financial year by the year in which it starts, e.g. 2000 refers to financial
year 2000/2001.
5Transfers from one provider to another one were considered an elective admission.
6PCTs were administrative organisations in place during our study period responsible for the
commissioning of primary and secondary heaalth care services. After the Health and Social care Act
of 2012, these were replaced by Clinical Commissioning Groups (CCGs)
7Figure 1, volumes for PTCA and CABG, presents all interventions retrieved from HES data from
2000/01 to 2012/13.
8Providers that have a high volume of PTCA but few for CABG (or vice versa) are kept. Providers
that have low volume levels at the beginning of the study period, but after show volumes above 50,
are kept for the whole period.
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50 providers only perform PTCA. In the empirical results presented below the analysis of
the sample of 79 hospitals can be interpreted as providing evidence on the aggregate NHS
impact that PTCA has on the workforce and the complementary technology (CABG), while
the analysis based on the 29 providers who undertake both procedures provides specific
evidence on hospital specific impacts.
Figure 1: Volume PTCA and CABG
Source: HES data.
Our dataset also contains HES provider-averaged information on case-mix such as the
percentage of male patients, percentage of emergency procedures, Charlson morbidity in-
dex, Index of Multiple Deprivation of the area where the patient resides, age and patient
comorbidities.9 We also include a number of provider characteristics such as whether they
have foundation trust status, bed occupancy rates, the total number of sites which the trust
occupies for health care service delivery, total annual cost for estate services and total annual
admission per provider10. In some specifications we also include the volume of statins (used
for primary and secondary prevention for cardiovascular disease) in each PCT to control for
the use of alternative non-surgical technologies that may reduce the need for PTCA/CABG.
Table A1 in the Appendix lists the variables used and provides some descriptive statistics.
HES data also includes an anonymised consultant code for the consultant in charge per-
forming the intervention. Based on this information, we compute the count of Full Time
Equivalent (FTE) consultants per provider and year associated with each intervention. We
distinguish between cardiologists, who perform PTCA in a catheterisation laboratory, and
cardiothoracic surgeons who perform CABG in an operating theater (Gray et al. 2000, Molina
9Comorbities have been computed as the sum of a number of main diseases defined per patient in
the HES data (diabetes, cancer, acute myocardial infarction, cerebral vascular accident, congestive
heart failure, connective tissue disorder, dementia, liver disease, peptic ulcer, peripheral vascular
disease, pulmonary disease, paraplegia, renal disease and HIV)
10Teaching trust is not included in the econometric specifications for consistency in the specifications
due to multicollinearity and in any case it reflects a fixed effect over time which is accounted for in
the empirical analysis.
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& Heng 2009). Figure 2 shows the count of FTE cardiologists and cardiothoracic surgeons in
our dataset performing PTCA and CABG, respectively. The figure shows that cardiologists
performing PTCA increased over the time period, with an average annual rate of growth of
6.96%, while the number of cardiothoracic surgeons performing CABG remained relatively
stable.
Figure 2: Cardiologist and Cardiothoracic surgeons
Source: HES data.
We also have data on the total count of cardiologists and cardiothoracic surgeons from
the NHS Electronic Staff Records (ESR). ESR provides information on FTE of medical
professionals detailed by seniority level; however, staff numbers from ESR on these two
medical specialty groups will be larger than the counts retrieved from HES data given that
not all cardiologists undertake PTCA and not all cardiothoracic surgeons perform CABG.
When looking at FTE counts in HES compared to FTEs in the ESR, HES data accounts for
68% of ESR cardiologist counts and 43% of cardiothoracic surgeons. This reflects the fact
that through the HES database we only identify the actual consultants who undertake PTCA
or CABG, whil the ESR database covers all cardiologists and caridothoracic surgeons. Figure
3 shows the increase in cardiologists and cardiothoracic surgeons by seniority level based on
ESR counts: consultants, specialists (Associate Specialist, Specialty Doctor, Staff Grade and
Specialty Registrar), and trainees (Core Medical Training, Foundation Doctor Year 1 and
Year 2). For the whole period of analysis (2000-2012), the average annual growth rate was
7.43% for all cardiologists; only slightly greater than the growth in cardiologists known to
perform PTCA (shown in Figure 2). In contrast with Figure 2, which showed a stable count
of cardiothoracic surgeons performing CABG, Figure 3 shows an average annual growth rate
of 5.16% in this specialty. The increasing numbers for all cardiothoracic surgeons is especially
striking from 2006 onwards given the markedly decreasing trend in CABG volumes in the
second half of our study period. This suggests the increase in cardiothoracic surgeons may
be driven by an increased volume of other surgical procedures performed by this specialty
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group.
Figure 3: Cardiologists (I) and Cardiothoracic Surgeons (II) by seniority level
(I) (II)
Source: ESR data.
The consolidation of PTCA over CABG seems to re-direct service provision by cardio-
thoracic surgeons to other surgical procedures. Using the anonymised consultant code for
cardiothoracic surgeons available in HES, we track all their surgical volume for all operations
other than CABG activity. We focus on the list of the main operations that fall into the
remit of cardiothoracic surgeons as specified by the Royal College of Surgeons.11 The list
of included cardiothoracic surgeries are valve replacement, pneumonectomy, wedge resection
and lobectomy. CABG and valve replacement are cardiac procedures, which is where our
explicit interest lies. While pneumonectomy, wedge resection and lobectomy are all thoracic
procedures, and although not of direct interest, we still consider them below. All surgical
volumes related to these alternative specialties were identified by the OPCS-4 code.12 Figure
4 shows the volume of these other cardiothoracic surgeons interventions. Tricuspid, pul-
monary and heart (K27-K29) are joined due to the low number of observations per provider
and year. While all are increasing over time, aortic valve replacement (K26) shows higher
volume increase, followed by mitral valve replacement (K25) and lung interventions(E54).
Such increases are compatible with the hypothesis of a shift in the composition of surgical
interventions performed by cardiothoracic surgeons.
11https://www.rcseng.ac.uk/news-and-events/media-centre/media-background-briefings-and-
statistics/cardiothoracic-surgery/
12OPCS-4 codes for: (1) Valve replacement are mitral-K25, aortic-K26, tricuspid-K27, pulmonary-
K28 and heart-K29; (2) pneumonectomy, wedge resection and lobectomy is E54
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Figure 4: Volume non-CABG interventions by Cardiothoracic Surgeons
Source: HES data.
3 Empirical Strategy
3.1 PTCA diffusion
We first examine the diffusion of PTCA at the provider level through a number of empirical
specifications. The diffusion model is based on specifications in Cutler & Huckman (2003)
and McGuire et al. (2010), accounting for the time-varying nature of the diffusion of PTCA
relative to CABG. As we are primarily interested in the impact of PTCA on the demand
for cardiologists who undertake angioplasty as opposed to CABG, we specify the dependent
variable as the PTCA volume in the following empirical specification:
PTCA
pop45 it
= α+ β1
CABG
pop45 it
+ (βs − β1)[CABG
pop45 it
∗ (ts)] + γ′Xit + Tt + ci + uit (1)
where the dependent variable is the population-adjusted PTCA volume by provider i
at year t and the main explanatory variable is population-adjusted CABG volume. We
interact the population-adjusted CABG volume with a vector of time indicators (2000-2002,
2003-2007, 2008-2012)13. By using time-varying coefficients we allow the interaction between
PTCA and CABG to vary over time, as we are specifically interested in these effects as
PTCA matures. Through Equation (1) we are able to quanitfy the elasticity of substitution
or complementarity between CABG and PTCA. We also include a set of control variables
Xit as defined in Section 2, year fixed-effects Tt, provider fixed-effect ci and the disturbance
term uit.
Other non-surgical technologies may influence the PTCA/CABG ratio trajectory. For
13These periods were decided based on the evolution of PTCA/CABG to differentiate between
periods of clear divergence between these technologies, as seen in Figure 1.
9
instance, statins are a class of cholesterol-lowering drugs prescribed for primary and secondary
prevention of cardiovascular disease. If primary prevention via medical treatment influences
the volume of surgical procedures the estimates in the results section may be upward biased
and the specification may suffer from potential omitted variable bias. We explicitly examine
the role that this non-surgical technology may has on the diffusion of PTCA. Data availability
is, however, restricted to the period 2008-2012 for which we have the total number of statins
prescribed at the Primary Care Trust (PCT) level.
3.1.1 PTCA indication creep
Having documented the degree of substitution as PTCA matures, we then examine the notion
of output expansion. We follow a similar specification to that in Equation 1 but now PTCA
becomes the main explanatory variable of interest, as we aim to analyse the spread of PTCA
to a wider patient pool for which CABG would have been deemed more appropriate. We
specifically consider the potential indication creep of PTCA, whereby PTCA is performed in
older and sicker patients as surgeons become more familiar with the technology. The explicit
indication creep specification is as follows:
CABG
pop it
= α+ β1
PTCA
pop it
+ (βs − β1)[PTCA
pop it
∗ (ts)] + β2Morbit
+ (βs − β1)[Morbit ∗ (ts)] + γ′Xit + Tt + ci + uit (2)
where CABG and PTCA are population-adjusted to different age groups (55-64, 65-
74, 75+) in order to test whether PTCA was progressively performed in older patients.
PTCA and CABG volumes are also interacted with the time dummies defined in Section 3.1
to examine whether there exist differences for the indication creep over time. In addition
to differentiating the expansion of PTCA across older patient groups, PTCA may also be
performed in sicker patients. To proxy for patient severity we have created a comorbidity
variable (Morb). The raw HES data records up to 14 comorbodities for each patient. From
this raw data, we calculate the average number of comorbities seen in patients by provider and
year. This ranges from an average number of 0 to 3 comorbidities across individual hospitals
per year. We then generate a dummy where a hospital has an average of no comorbidities,
one comorbidity, and an average of more than one comorbidity in the patient population.
The reference category is zero commorbities and we also interact these dummies with time
periods.
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3.2 Elasticity of substitution
Next we turn to our central empirical analysis that quantifies the elasticity between workforce
and the PTCA/CABG ratio, which we initially assess using a static panel model:
WFit = α+ β1
PTCA
CABG it
+ γ
′
Xit + Tt + ci + uit (3)
where the dependent variable WFit is the ratio between two counts of different FTE in the
workforce. The underlying assumption is that if PTCA volume has been increasing over
time this will theoretically be associated with a change in the workforce skill mix; that is, an
increase in cardiologists relative to cardiothoracic surgeons. We therefore examine the ratio
of labour types relating to the provision of PTCA/CABG in Equation 3, where WFit is the
log of the ratio of cardiologists (C) over cardiothoracic surgeons (CS) per provider i and year
t.
The point estimate β1 is likely to be biased due to the potential endogeneity arising
from the simultaneity of the workforce composition and the PTCA/CABG relationship. As
result, we pursue different estimation strategies to overcome this endogeneity. First, we
implement a Two-State Least Square (2SLS) - Instrumental Variable (IV) approach in a
static equation. In the first stage (Equation 4), we model the PTCA/CABG ratio on patient
and providers’ characteristics and the instrument Zit reflects access to health care services, as
based on referrals from the General Practitioner (GP) practices where the treatment patients
are registered.This IV, we believe is individually correlated with the volume of PTCA to
CABG procedures undertaken by the specified provider, operating through a mechanism
that associates increases in procedure rates with increases in access to treatment procedure,
but is not directly related to the provider employment ratio of cardiologists to cardiothoracic
surgeons.
PTCA
CABG it
= α+ β
′
Zit + γ
′
Xit + +Tt + ci + uit (4)
We consider two definitions for the instruments used in the first stage: 1) the distance
of the referring GP to the provider; and 2) the number of GPs referring to each provider.
For both IVs, we first calculate geographical areas from which each hospital could draw
potential patients. These areas are based on referral patterns and distances travelled by
patients, using their GP practice as their proxy for residence. In computing the distance of
individual GP practices to the hospital, we first calculate the radial distance of 50km around
each provider to define referring GP practices. This radial measure is commonly used in
the provider competition literature. Within this 50km radius, we identify GP practices who
contributed at least 30% of a hospital’s referred patients, where this cutoff was chosen to
avoid exceptional patient referral patterns. This defines the geographical area from which
each hospital draws its patient population.
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For the IV based on distance, we use this geographical area which defines the total
population served by each hospital and we calculate four distinct IVs based on the mean,
median, 75th percentile and 90th percentile of the distance from the referring GP practice to
the hospital. Our preferred measure relates to a geographical area based on a radial distance
of 50km and 30% of referred patients, and the 75th percentile IV estimate. For the IV based
on GP numbers we use the total number of practices within the defined geographical area
(i.e. radial distance of 50km and 30% of referred patients).
Using the predicted PTCA/CABG values from Equation 4, in the second stage of the
2SLS we estimate the following:
WFit = α+ β1
̂PTCA
CABG it
+ γ
′
Xit + ci + Tt + vit (5)
This 2SLS estimation procedure is one means of solving for the endogeneity between
workforce composition and the PTCA/CABG ratio. However, it reflects a static approach
while more plausibly the relationship between treatment procedure adjustments and work-
force composition is a dynamic one, reflecting lags due to training and/or staff redeployment.
As a result, we also consider a dynamic panel data approach and estimate the following spec-
ification:
WFit = α+ β1WFit−1 + β2
PTCA
CABG it
+ γ
′
Xit + Tt + ci + uit (6)
The system GMM estimator proposed by Blundell & Bond (1998) and Bond (2002)
obtains consistent estimators, with first-differences taken to eliminate ci and remove any bias
caused by the correlation of ci and the lagged dependent variable. As the first difference of the
lagged dependent variable is now correlated with the first-differenced error component, an IV
structure must be used in order to obtain consistent estimates. To control for the correlation
between the lagged dependent variable WFit−1 and the error term we use as IVs the following
lags: 1) WFit−2, WFit−3, WFit−4 and WFit−5 for equations in first-differences; and 2)
∆WFit−1, ∆WFit−2, ∆WFit−3 and ∆WFit−4 for the equations in levels, where ∆WFit−1 =
WFit−1 −WFit−2.
We further address the problem of endogeneity by using the same instruments outlined for
estimating Equation (4) within a final specification of the dynamic structure. We also exploit
the flexibility of the system GMM estimator and use lagged values of the PTCA/CABG ratio
with the same structure to the instrument set used for WFit−1.
3.2.1 Cardiothoracic surgery displacement
Our descriptive analysis in Section 2 suggests that while there is a decrease in CABG volume
over time, the count of cardiothoracic surgeons increases (see Figure 3) along with the volumes
of other surgical subspecialties that this workforce group undertakes (see Figure 4). We
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empirically analyse the potential displacement activity of cardiothoracic surgeons to other
interventions, as CABG volumes decline. For each consultant performing CABG identified
in our sample over the study period, we track volumes of all other activity undertaken in a
give year. Specifically, we consider a specification similar to that given as Equation (1), with
the main difference being that the analysis is now at the consultant level:
CABG
pop45 ijt
= α+ β1
otherCS
pop45 ijt
+ (βs − β1)[otherCS
pop45 ijt
∗ (ts)] + γ′Xijt + Tt + ci + uijt (7)
where the population-adjusted CABG volume performed by consultant j in i at time t is
regressed on the volume of other cardiothoracic surgical interventions, (otherCS), controlling
for the population at risk and interacted with time-periods. As described above, the other
cardiothoracic volumes considered are valve replacement (mitral-K25, aortic-K26, tricuspid-
K27, pulmonary-K28 and heart-K29) and lung interventions (pneumonectomy, wedge resec-
tion and lobectomy - E54).
4 Results
4.1 Technology diffusion
4.1.1 Basecase results
Table 1 presents the results of estimating the degree of substitution/complementarity between
our two technologies as in Equation 1. The dependent variable is the volume of PTCA
over the population aged 45 and above (in 1000s) and the main explanatory variable is the
corresponding measure for CABG. Table 1 shows the estimates of a fixed-effects panel data
model. In this Table, the columns report the estimates for the whole sample, 79 providers,
and for the subsample of 29 providers performing both procedures, for the period 2000-2012.
Each interaction term represents a change in the CABG rate coefficient relative to 2000-2002.
The results in Table 1 confirm that complementarity exists between these two technologies
(all estimates are positive and statistically significant) for the period of our study, reflecting
the maturing phase of the new technology. Based on these estimates, our measure of overall
elasticity indicate that 1% increase in CABG volumes, increases PTCA volumes by 26% in the
sample of 79 and 34% in the 29 subsample. The interaction terms (marginal complementarity)
are positive and significant for column 1 and 2. However, there is a significant decrease in
the estimates from 2003-2007 to 2008-2012 compared to the baseline period 2000-2002. This
decrease in marginal complementarity may be due to PTCA being increasingly expanded
over time to older patients and/or patients with more comorbidities, in what we term as the
”indication creep” effect.
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Volumes for both PTCA and CABG may respond to the competition introduced by
non-surgical, medical technologies to treat cardiovascular disease. Statins are cholesterol
lowering drugs that are prescribed for primary prevention for cardiovascular disease, and
wider use of this drug type may translate into reduced need for the use of PTCA or CABG. In
columns 3 and 4 we also include the log of statins to control for other non-surgical competing
technologies that may affect the volume of PTCA. The sample now only covers the period
2008-2012, as prescription information was only available for this period. The results reported
in Table 1 indicate that statins are substitutes (negative in sign) although the estimates
are not precisely estimated, possibly reflecting the reduction in sample size due to data
availability for statins.
Table 1: Technology Diffusion: Basecase Results
Dep.Var: PTCA/45+ (1) (2) (3) (4)
CABG/45+ 0.534** 0.523* 0.567 0.408
(0.216) (0.261) (0.352) (0.426)
CABG/45+*(2003-2007) 0.706*** 0.849***
(0.134) (0.279)
CABG/45+*(2008-2012) 0.338*** 0.467***
(0.108) (0.118)
Log Statins -3.450 -4.005
(5.009) (9.669)
No. Hospitals 79 29 75 29
N 856 363 362 144
Time fixed-effects Yes Yes Yes Yes
Provider fixed-effects Yes Yes Yes Yes
Controls Patients Yes Yes Yes Yes
Controls Provider Yes Yes Yes Yes
R2 0.464 0.559 0.171 0.339
Years 2000-2012 2000-2012 2008-2012 2008-2012
Notes: Robust standard errors in parentheses. Significance levels: *** p<0.01, **
p<0.05, * p<0.1. Control variables: percentage of male patients, percentage of
emergency procedures, charlson morbidity index, Index of Multiple Deprivation of
the area where the patient resides, mean age, percentage of population over 45 by
PCT, bed occupancy rate, total number of admissions, total number of sites, estate
service cost and foundation trust dummy.
4.1.2 Indication creep
Having documented the degree of complementarity as PTCA matures, we now examine ex-
plicitly the notion of output expansion associated with the PTCA ”indication creep” effect.
We do so following the specification in Equation 2 to quantify the potential expansion effect
of PTCA to patients that are sicker and older. Table 2 presents the results of interacting
PTCA volumes (and their corresponding time interactions) with age groups and with the
average number of comorbidities in patients treated by specific providers in any given year
to capture any indication creep, for both samples, the sample that includes all 79 providers
and the sample that includes the 29 providers that do both PTCA and CABG. Each column
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represents a patient group of different age (55-64, 65-74 and 75+) and the PTCA volume
is again interacted with time dummies. In each column we also include dummies account-
ing for moderate (Morb1 ) to high (Morb2 ) patient risk as proxied by the average level of
comorbidities, with the reference category being no commorbidities.These dummies are also
interacted with time periods. For the subsample with 29 providers, the high commobidities
dummy has zero observations for the first period. As a result, the baseline is period 2.
These results support the general notion of indication creep in PTCA treatment over time.
For the sample of 79 hospitals, there is a significant substitution effect specially in the third
period (2008-2012) for age groups 55-64 and 65-74, while there is a significant complementary
effect in the same period for 75+. The estimates for the comorbidity dummies suggest that
overall CABG volumes were higher for patients with comorbidities with respect to those
with no comorbidities for the 55-64 age group. However, this effect is reversed towards later
stages of diffusion as indicated by the interaction terms. For patients in the 65-74 and 75+
age groups, there is only some evidence for sicker patients to be less likely to have CABG
but only towards the end of the study period. Results for the subsample of 29 hospitals
indicates a stronger overall effect of morbidity for moderate risk levels on CABG volume
consistent across age groups with evidence again that during the 2003-2007 diffusion period
CABG volumes were reduced for patients with moderate risk. There is weaker evidence that
sicker patients will receive CABG in the 2008-2012 period compared to 2003-2007.
4.2 Technology diffusion and workforce effects
Turning to our central question on the workforce effects, we present two sets of results.
First, Table 3 presents the static results for both samples, with all 79 hospitals and only
the subsample of 29 hospitals performing both PTCA and CABG. Columns 1 and 2 show
the results for the OLS estimator. The workforce elasticity is 0.34 for the full sample and
0.24 for the sample with 29 hospitals. The results in Columns 3 and 4 show the estimates
obtained using a fixed-effects panel data model, elasticities between 0.25 and 0.42. To address
the potential endogeneity arising from the reverse causality of workforce and PTCA/CABG
ratio, we show in columns 5-8 the 2SLS estimates using both IVs based on the geographical
area defined by a radial distance of 50km and 30% referral rate. Columns 5 and 6 show the
IV defined as the distance from the GPs to each provider based on the 75th percentile and
Columns 7 and 8 show the results when using the number of GPs in this geographical area.
These results show a positive and significant effect of the ratio of PTCA over CABG
on the ratio of cardiologist over cardiothoracic surgeons. This is consistent with an increase
(decrease) in PTCA (CABG) treatments resulting in increases (decreases) in cardiologists
(cardiothoracic surgeon) staffing levels. The elasticities are estimated precisely only in the
sample with all 79 hospitals, as seen in Columns 5 and 7. When endogeneity is purged with
the 2SLS in the whole sample the resulting coefficient decreases from 0.4 to 0.3, and this is
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Table 2: PTCA Indication Creep
(1) (2) (3) (4) (5) (6)
Dep. Var: CABG/55-64 CABG/65-74 CABG/75+ CABG/55-64 CABG/65-74 CABG/75+
PTCA/55-64 0.217*** 0.209***
(0.0647) (0.0653)
PTCA/55-64*(2003-2007) -0.0845* -0.0502
(0.0469) (0.0376)
PTCA/55-64*(2008-2012) -0.141** -0.0939*
(0.0563) (0.0482)
PTCA/65-74 0.278*** 0.291***
(0.0806) (0.0899)
PTCA/65-74*(2003-2007) -0.0584 -0.0457
(0.0587) (0.0577)
PTCA/65-74*(2008-2012) -0.141* -0.129
(0.0835) (0.0869)
PTCA/75+ 0.0662 0.193***
(0.0726) (0.0695)
PTCA/75+*(2003-2007) 0.157*** 0.0674
(0.0558) (0.0582)
PTCA/75+*(2008-2012) 0.165*** 0.0406
(0.0580) (0.0588)
Morb.1 0.852** 0.796 -0.0401 4.354*** 6.418*** 2.094***
(0.366) (0.609) (0.331) (0.898) (1.458) (0.654)
Morb.1*(2003-2007) -0.790** -0.799 -0.0727 -6.437** -8.129* -4.479
(0.372) (0.582) (0.392) (2.330) (4.402) (2.688)
Morb.1*(2008-2012) -0.409 -0.560 -0.325 -1.034 -1.188 0.189
(0.324) (0.592) (0.297) (0.642) (1.381) (0.759)
Morb.2 0.404* 0.541 0.293 -3.391* -2.971 -1.632
(0.238) (0.416) (0.268) (1.931) (3.931) (2.572)
Morb.2*(2003-2007) -0.412 -0.474 -0.201
(0.251) (0.408) (0.292)
Morb.2*(2008-2012) -0.340 -0.871** -1.337*** 6.072** 7.232 3.104
(0.219) (0.428) (0.339) (2.433) (4.839) (3.072)
No. Hospitals 79 79 79 29 29 29
N 856 856 856 363 363 363
Year FE Yes Yes Yes Yes Yes Yes
Provider FE Yes Yes Yes Yes Yes Yes
Controls Patients Yes Yes Yes Yes Yes Yes
Controls Providers Yes Yes Yes Yes Yes Yes
R2 0.437 0.365 0.522 0.564 0.448 0.615
Year 2000-2012 2000-2012 2000-2012 2000-2012 2000-2012 2000-2012
Notes: See Notes in Table 1. Robust standard errors in parentheses. Significance levels: *** p<0.01, ** p<0.05, * p<0.1.
consistent regardless of the IV used. The estimates in the specifications using the subsample
of 29 hospitals (columns 6 and 8), the elasticities are insignificant and even wrong signed
(column 6). All IV models fulfill the F statistic exclusion restriction (F>=10), except for the
model in column 6.
Estimates in columns (5) and (6) in Table 3 were obtained using the distance IV based
on the 75th percentile of distance within the geographical area (50km radial distance and the
30% of referred patients). We also estimated coefficients using the mean, median and 90th
percentile within these areas and results are available in Table A2 in the Appendix. Similar
to results in Table 3, once instrumenting the PTCA/CABG ratio we lose significance of the
elasticity measure for the subsample of 29 hospitals, with exception of the specification that
includes the 90th percentile. The fact the estimates are more precisely estimated when using
higher percentile values might suggest that these measures are a better reflection of patient
16
access than those based on the mean and median distance, allowing better capture of the
treatment population. We also estimated our coefficients of interest using the distance IV
with a definition of geographical area based on a cut-off point of 37km instead of 50km (37km
being the average distance for the whole sample). Results are reported in Table A3 in the
Appendix and are comparable to those in Table 3.
The second set of workforce composition results report our preferred dynamic specifica-
tion, as outlined in Equation 6, that accounts for any workforce adjustment costs. Table
4 presents the different dynamic estimations for both the 79 and the 29 hospitals. As a
baseline, the first 4 columns show the results of a dynamic OLS and fixed-effects panel es-
timation, which we presume are biased due to endogeneity through both the lagged value
of the dependent variable and the PTCA/CABG ratio. Columns 5 through 12 present the
system GMM estimations. Results in columns 5 and 6 only instrument the lagged dependent
variable using up to four lag periods but do not instrument the PTCA/CABG variable. The
estimated workforce elasticity is 0.28 for the whole sample and 0.24 for the subsample of 29
hospitals.
In columns (7) through (12) we report the results instrumenting for the PTCA/CABG
ratio endogeneity. We first use in columns (7) to (10) using the same IVs as in Table 3 based
on the distance from GP to provider to define patient access and count of GPs referring to
each hospital. As explained above, both IVs are based on the geographical areas defined by
the 50km radial distance and the 30% of referred patients. Results show that the coefficient
relating to the effect of workforce redeployment (as represented by the lag of the dependent
variable) is positive and highly significant across all these corrected estimations, except in
column (10).
Our preferred specification is reported in columns (11) and (12) using a dynamic structure
with instruments based on lags and differences as proposed by Blundell & Bond (1998). By
using lags of the endogenous variable in the differenced and levels equations in system GMM,
the number of instruments may be too large compared to the sample size leading to potentially
unreliable p-values for the Hansen test of instrument validity. We take two approaches in
order to address this problem. We restrict the number of instruments to up to four lags and we
also collapse the instrument matrix as suggested by Roodman (2009). The results show that
a 1% increase in the PTCA/CABG relationship, increase the C/CS ratio by 0.27% for the
sample of 79 and by 0.6% for the subsample of 29 hospitals. Descriptive evidence presented
in Section 2 (see Figure 2) show that the number of cardiothoracic surgeons remained stable
over time, implying that the cardiologist count is increasing, although at a somewhat lower
rate than the PTCA treatment volume.
These preferred dynamic IV models are supported by several specification tests. We fail
to reject the null hypotheses of valid overidentifying restrictions in the Hansen test for all
specifications. The p-value for the test of no first-order autocorrelation fails to reject the null
17
hypothesis, while the null of no second-order autocorrelation is not rejected. As showed by
Arellano & Bond (1991) the presence of first-order autocorrelation does not affect the con-
sistency of the specification of the model as long as there is no second-order autocorrelation,
therefore our estimates remain consistent under the presence of first-order autocorrelation.
We also tested for unit root using the Fisher-type unit-root test, based on the augmented
Dickey-Fuller and the Phillips-Perron tests, and our variables of interest (i.e. Log C/CS and
Log PTCA/CABG) rejected the null hypothesis of all panels contain unit-roots.
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As a further robustness check, and to give some precision to workforce composition effects,
Table 5 follows the dynamic specification of Table 4 using workforce counts from the ESR
data. ESR records all cardiologists and cardiothoracic surgeons working in the NHS, but,
as discussed in Section 2, the ESR data gives larger counts of workforce because not all
cardiologists and cardiothoracic surgeons perform PTCA or CABG. While we cannot link
individual workforce from ESR to the treatment procedures we analyse, as we do for HES
data, the ESR data have detailed data on workforce seniority levels that allows us to break
down the impact of the maturing use of PTCA by staff grade, as there are data on counts
of consultants (attending or chief resident physician), specialists (residents) and trainees
(fellows) at individual provider and year level.
Instead of reporting alternatively for the 79 hospitals and then for the 29 provider subsam-
ple, Table 4 reports on staffing levels first for the 79 providers and then for the 29 providers.
Generally the PTCA/CABG ratio is positive and supportive of earlier results, except for
trainees where the coefficients are negative, significantly so for the 29 hospital providers.
Columns (1) and (5) show the results when including the overall count of workforce (sum of
the three staff groups). This result is consistent with the results using HES data (columns
(11) and (12) in Table 4), but not surprisingly the coefficients are significantly lower. This
can be explained by the differences between HES workforce count, which reflects the ac-
curate count of physicians performing PTCA or CABG, compared to ESR, which has the
total count of physicians in these two surgical specialties, and therefore the results may be
downward biased. The workforce elasticity is very similar for consultants and specialists, be-
coming negative for trainees. This negative elasticity may indicate that less cardiologists are
trained (relative to cardiothoracic surgeons) to deal with PTCA volumes, reflecting either a
shortage of cardiologists being trained or increases in cardiologists’ labour productivity such
that lower counts are required to meet PTCA volumes.
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4.2.1 CABG vs other cardiothoracic surgeons’ interventions
If CABG volumes have been decreasing over time, we would expect individual consultant
productivity for cardiothoracic surgeons to decrease. Instead, we observe an increase in
volumes of the other cardiac procedures that cardiothoracic surgeons perform. In order to
investigate this displacement activity, we examine the level of substitution across alternative
interventions undertaken by this workforce group. Table 6 presents the estimates of a pooled
OLS with year and provider fixed-effects at the consultant level, where CABG is regressed
on the volume of other cardiothoracic surgeons’ interventions (interacted with time periods).
The same consultant may practice in different providers therefore we could not use a fixed-
effects panel model. As explained in the data section, the other main interventions are
valve replacement (mitral-K25, aortic-K26, tricuspid-K27, pulmonary-K28 and heart-K29)
and lung interventions (pneumonectomy, wedge resection and lobectomy - E54). Table 6
shows the estimates only for the consultants identified in HES as performing CABG, who
are only observed in the subsample of the 29 hospitals. The difference between the first two
models and the last two is that models in columns 3 and 4 also include controls for patients
and providers.
The results are very similar whether controls are or are not included. Columns (1) and
(3) present results aggregating all valve replacement interventions (K25-K29). Columns (2)
and (4) show the estimates when all valve replacement procedures are disaggregated by
individual valve replacement interventions (K25,K26,K27-K29). Results show a significant
substitution effect between volumes of valve replacement and CABG for the third period
(2008-2012) compared to the baseline period. In the specifications that dissagregate valve
replacement types results show a significant substitution effect for periods 2 (2003-2007) and
3 (2008-2012) for K25 and K26, but not for K27-K29 where there seems to be a significant
complementarity among these procedures. For thoracic interventions (E54), the effect is not
significant simply reflecting that the direct competition is between CABG and the other type
of cardiac procedures, not between cardiac and thoracic types. This reinforces the idea that
as CABG decreases, and with a relatively stable number of cardiothoracic surgeons over time,
the reduction in CABG volume is substituted by an increasing volume of valve replacements.
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Table 6: CABG Displacement
Dep. Var: CABG/45+ (1) (2) (3) (4)
K25-K29 1.820*** 1.725***
(0.233) (0.216)
K25-K29*(2003-2007) -0.252 -0.244
(0.195) (0.182)
K25-K29*(2008-2012) -0.977*** -0.953***
(0.257) (0.238)
K25 13.442*** 12.770***
(4.629) (4.590)
K25*(2003-2007) -9.634*** -8.892***
(2.737) (2.442)
K25*(2008-2012) -11.710** -11.147**
(4.369) (4.456)
K26 15.408*** 14.713***
(4.586) (4.554)
K26*(2003-2007) -9.020*** -8.297***
(2.303) (1.987)
K26*(2008-2012) -11.887*** -11.389***
(4.118) (4.193)
K27-K29 -12.696*** -12.100**
(4.621) (4.598)
K27-K29*(2003-2007) 8.972*** 8.259***
(2.425) (2.154)
K27-K29*(2008-2012) 10.903** 10.405**
(4.109) (4.216)
E54 0.535* 0.383 0.472 0.324
(0.297) (0.298) (0.281) (0.279)
E54*(2003-2007) -0.235 -0.224 -0.237 -0.213
(0.293) (0.297) (0.280) (0.284)
E54*(2008-2012) -0.484 -0.411 -0.449 -0.359
(0.288) (0.294) (0.268) (0.270)
No. Hospitals 29 29 29 29
N 2883 2883 2839 2839
Year FE Yes Yes Yes Yes
Provider FE Yes Yes Yes Yes
Controls Patients No No Yes Yes
Controls Providers No No Yes Yes
R2 0.5443 0.6088 0.5624 0.6220
Years 2000-2012 2000-2012 2000-2012 2000-2012
Notes: See Notes in Table 1 for controls included.Standard errors (in parentheses) clustered
at the provider level. Significance levels: *** p<0.01, ** p<0.05, * p<0.1. The same con-
sultant may practice in different providers therefore we could not use a fixed-effects panel
model. Estimates obtained using a pooled OLS with year and provider fixed-effects.
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5 Discussion
The objective of this paper was to consider the full impact of a maturing new technology
on workforce composition in the English NHS. We examine two competing technologies for
treating cardiovascular disease: CABG, an open procedure first introduced, and PTCA, a
less invasive and cheaper procedure. Each of these surgical technologies are performed by
a different set of physicians in the NHS. CABG is performed by cardiothoracic surgeons
and PTCA by cardiologists. This allows us examining changes in workforce of the same
skill type arising from technology change. We use two major UK administrative databases
to undertake our analysis: the Hospital Episodes Statistics (HES) and the NHS Electronic
Staff Records (ESR). HES allows specific identification of the consultants (cardiologists and
cardiothoracic surgeons) undertaking PTCA or CABG. ESR identifies all NHS cardiologists
and cardiothoracic surgeons, providing greater detail on staffing levels by seniority levels.
Through analysing the maturing of PTCA as a partial replacement for CABG, we first
documented complementarity effects across the two technologies. The estimated elasticity
indicated complementarity, reflecting the maturity in the uptake of PTCA, with a 1% increase
in CABG volumes associated with an increase in PTCA volumes of 26% in the sample of
all 79 providers and 34% in the subsample of 29 hospitals undertaking both procedures.
This builds on previous research on the topic that found a substitution effect across these
technologies in earlier time periods (Cutler & Huckman 2003, McGuire et al. 2010). However,
these studies did no look at the mechanisms through which the increasing use of PTCA leads
to output expansion. Our results suggest that this PTCA output expansion is associated
with indication creep. This resulted in PTCA treatment being offered to increasing numbers
of elderly and comorbid patients.
Secondly, we computed estimates of the degree to which the workforce reacts to the
introduction of new technology, based on elasticity of supply measures by adopting two dif-
ferent approaches, a static and a dynamic approach. Both empirical approaches addressed
the potential endogeneity caused by the reverse causality of the PTCA/CABG treatment
ratio on the workforce ratio, as measured by the distinct staff categories of cardiologists and
cardiothoracic surgeons employed to undertake these treatment technologies. The matur-
ing phase of PTCA was found to be associated with a positive and significant effect of the
PTCA/CABG ratio on the workforce ratio (cardiologist over cardiothoracic surgeons). The
trends exposed by our graphical analysis and the established relative complementarity be-
tween PTCA and CABG supports a growth in the number of cardiologists as compared to a
flattening of the employment of cardiothoracic surgeons. The witnessed growth in cardiolo-
gists holds for the investigations based on both the HES data and ESR data. Our preferred
dynamic specification reveals that a 1% increase in the PTCA/CABG relationship, increases
the WF ratio by 0.27% for the sample of 79 and by 0.6% for the subsample of 29 hospitals.
As cardiothoracic surgeon employment for CABG was stable over time, the 0.27% or 0.6%
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increase reflects purely a relative growth in cardiologists. As a result, cardiologist count is
increasing, although at a somewhat lower rate than the PTCA treatment volume.
The workforce elasticity estimate is greater for the subsample of 29 providers that perform
the two interventions. Throughout our analysis we have presented results using the sample
of 79 providers (that includes the 29 hospitals that undertake both PTCA and CABG but
also 50 providers who only undertake PTCA) and for the subsample of 29 providers. The
full sample of 79 hospitals represents the aggregate impact across the NHS of the workforce
reaction, while the impact for the subsample of 29 providers details an accurate account of
workforce adjustments for those providers performing both interventions.
Finally, our last analysis covered the displacement of CABG volume to other interven-
tions, finding that as CABG volume decreases the volume of valve replacement interventions
increased and accounts for the levelling off, rather than any decrease, in the employment
of cardiothoracic surgeons. We provide evidence of the substitution between CABG and
the other cardiac interventions undertaken by these workforce group. Whether this increase
in volume of other treatments reflects a compensating induced mechanism in the form of
supplier-induced demand by the cardiothoracic surgeons or merely the ability of these sur-
geons to address pent-up demand in other treatment areas is something our analysis does
not address.
Little is known about the substitution of workforce across the health care sector, and
there is little knowledge relating to the technology-labour substitution. If technology is,
as seems to be the case, a major driver of health care expenditure growth the aggregate,
examining general impacts of new technology up-take on staffing levels and composition is
key to understand future workforce planning. Further research is required to check whether
our findings are replicated across other areas of technology, and across a wider range of
staffing categories. Data restrictions on staffing levels prevented investigation of the latter in
our case.
Overall, our results suggest that, at least in this area of health care, new technology
up-take and diffusion does affect the skill mix of the medical workforce as the technology
matures. While our results are confined to specific highly prevalent technologies, it appears
that the complex regulation of staffing and specialty mix is even further complicated once
account is taken for the impact of new technology on the hospital production process. Skilled
staff appear to be able to substitute into new tasks adjusting to exogenous technology change.
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Appendix
Table A1: Variables Definition and Descriptive Statistics (2000-2012)
Variable Definition Source N Mean St.Dev
v ptca PTCA volume HES 870 643.732 657.997
v cabg CABG volume HES 870 250.537 324.417
p emergency % emergency operations HES 870 0.31 0.281
p males % male patients HES 870 0.732 0.160
age Age patients HES 870 64.23 49.62
comorbidities Comorbidities patients (0-3) HES 870 0.802 0.357
imdi Index of Multiple Deprivation (IMD)
income
HES 870 0.138 0.050
charlson Charlson Comorbidity Index HES 870 4.418 2.33
ftrust =1 if provider has FT status HES 870 0.317 0.466
teaching =1 if teaching status ERIC 870 0.323 0.468
occuprate Overnight bed occupancy rate NHS England 869 85.066 5.44
#sites # sites the trust occupies for services
delivery
ERIC 868 6.987 8.889
estatescost Annual revenue cost (£000,000) to pro-
vide the whole of the Estate services
ERIC 858 17 18.8
Pop45 % population aged 45 and above 45 by
PCT
ONS 870 38.467 6.694
Admissionspop total admissions adjusted by popula-
tion
ONS 870 321.348 213.372
dptcacabg =1 if provider has high volumes (above
50) of PTCA and CABG
HES 870 0.424 0.495
dptca =1 if provider has high volumes (above
50) of PTCA and low CABG volumes
HES 870 0.576 0.495
C # FTE doctors performing PTCA HES 870 13.969 10.608
CS # FTE doctors performing CABG HES 870 3.326 3.977
C: # FTE cardiologists ESR
c consultant Consultants 870 7.387 4.674
c specialist Specialists 870 8.081 7.34
c trainees Trainees 870 2.840 3.802
CS: # of FTE cardio surgeons ESR
cs consultant Consultants 870 3.502 4.624
cs specialist Specialists 870 4.463 6.555
cs trainees Trainees 870 0.895 2.009
statins Number of items prescribed (2008-
2013) at PCT level
NHS Digital 363 501569.4 284118.6
v otherCSint Volume other CS interventions K25-
K29 & E54
HES 870 106.349 142.297
Distance P75 Distance from GPs to provider HES 766 21.043 10.782
No. GPs Number of GPs referring patients to
each provider
HES 766 142.704 128.288
Notes: p males, imdi, charlson, p emergency, age and comorbidities are averages over patients treated by hospital i in year t. HES
(Hospital Episodes Statistics). ONS (Office for NAtional Statistics) ESR (Electronic Staff Records). ERIC (Estates Return Information
Collection) from Hospital Estates and Facilities Statistics.
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